Vista Pharmaceuticals is currently trading at its upper circuit limit of Rs. 32.70, up by 1.55 points or 4.98% from its previous closing of Rs. 31.15 on the BSE.
The scrip opened at Rs. 31.40 and has touched a high and low of Rs. 32.70 and Rs. 31.40 respectively. So far 63933 shares were traded on the counter.
The BSE group 'XT' stock of face value Rs. 2 has touched a 52 week high of Rs. 47.95 on 17-Apr-2017 and a 52 week low of Rs. 15.50 on 22-Nov-2016.
Last one week high and low of the scrip stood at Rs. 35.25 and Rs. 31.15 respectively. The current market cap of the company is Rs. 87.64 crore.
The promoters holding in the company stood at 31.19%, while institutions and non-institutions held 0.05% and 68.75% respectively.
Vista Pharmaceuticals has received a warning letter from the US Food & Drug Administration (USFDA) for significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals at its formulation plant located at Nalgonda district in Telangana. The US regulator had inspected the said plant from September 19 to 23, 2016 and issued Form 483 observations.
Vista Pharmaceuticals is engaged in manufacturing and selling of pharmaceutical, medical and veterinary preparations. The company also sells the products to its related companies, which are engaged in the manufacture of formulations.